



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Influence of Nodal signalling on pluripotency factor expression, tumour cell proliferation and cisplatin-sensitivity in testicular germ cell tumours

Citation for published version:

Harpelunde Poulsen, K, Nielsen, JE, Grønkær Toft, B, Joensen, UN, Rasmussen, LJ, Blomberg Jensen, M, Mitchell, RT, Juul, A, Rajpert-de Meyts, E & Jørgensen, A 2020, 'Influence of Nodal signalling on pluripotency factor expression, tumour cell proliferation and cisplatin-sensitivity in testicular germ cell tumours', *BMC Cancer*, vol. 20, no. 1. <https://doi.org/10.1186/s12885-020-06820-6>

Digital Object Identifier (DOI):

[10.1186/s12885-020-06820-6](https://doi.org/10.1186/s12885-020-06820-6)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

BMC Cancer

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



[Click here to view linked References](#)

1 **Influence of Nodal signalling on pluripotency factor expression, tumour cell proliferation and cisplatin-**
2
3 **sensitivity in testicular germ cell tumours**
4

5
6
7
8 K. Harpelunde Poulsen^{1,2}, J.E. Nielsen^{1,2}, B. Grønkær Toft³, U.N. Joensen⁴, L. J. Rasmussen⁵, M. Blomberg
9
10 Jensen¹, R.T. Mitchell⁶, A. Juul^{1,2}, E. Rajpert-De Meyts^{1,2} and A. Jørgensen^{1,2*}.
11
12
13
14

15 ¹Department of Growth and Reproduction, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9,
16
17 2100 Copenhagen, Denmark.
18

19
20 ²International Research and Research Training Centre in Endocrine Disruption of Male Reproduction and
21
22 Child Health (EDMaRC), Blegdamsvej 9, Copenhagen, Denmark.
23

24
25 ³Pathology Department, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, 2100
26
27 Copenhagen, Denmark.
28

29
30 ⁴Department of Urology, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, 2100
31
32 Copenhagen, Denmark.
33

34
35 ⁵Department of Cellular and Molecular Medicine, Center for Healthy Aging, University of Copenhagen,
36
37 Blegdamsvej 3B, 2200 Copenhagen, Denmark.
38

39
40 ⁶MRC Centre for Reproductive Health, The Queen's Medical Research Institute, University of Edinburgh,
41
42 47 Little France Crescent, Edinburgh EH16 4TJ, UK.
43

44
45 *Corresponding author: Anne Jørgensen, Department of Growth and Reproduction, Rigshospitalet,
46
47 University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Tel: +45 35458908, Email:
48
49 aj@rh.regionh.dk
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 **Abstract**

2
3 **Background:** Testicular germ cell tumours (TGCTs) are characterised by an overall high cisplatin-sensitivity
4
5 which has been linked to their continued expression of pluripotency factors. Recently, the Nodal signalling
6
7 pathway has been implicated in the regulation of pluripotency factor expression in fetal germ cells, and the
8
9 pathway could therefore also be involved in regulating expression of pluripotency factors in malignant
10
11 germ cells, and hence cisplatin-sensitivity in TGCTs.
12
13

14
15 **Methods:** We used *in vitro* culture of the TGCT-derived cell line NTERA2, *ex vivo* tissue culture of primary
16
17 TGCT specimens and xenografting of NTERA2 cells to investigate the consequences of manipulating Nodal
18
19 and Activin signalling on pluripotency factor expression, apoptosis, proliferation and cisplatin-sensitivity.
20
21

22
23 **Results:** The Nodal signalling factors were markedly expressed concomitantly with the pluripotency factor
24
25 OCT4 in GCNIS cells, seminomas and embryonal carcinomas. Despite this, inhibition of Nodal and Activin
26
27 signalling either alone or simultaneously did not affect proliferation or apoptosis in malignant germ cells *in*
28
29 *vitro* or *ex vivo*. Interestingly, inhibition of Nodal signalling *in vitro* reduced the expression of pluripotency
30
31 factors and Nodal pathway genes, while stimulation of the pathway increased their expression. However,
32
33 cisplatin-sensitivity was not affected following pharmacological inhibition of Nodal/Activin signalling or
34
35 siRNA-mediated knockdown of the obligate co-receptor *CRIPTO* in NTERA2 cells *in vitro* or in a xenograft
36
37 model.
38
39

40
41 **Conclusion:** Our findings suggest that the Nodal signalling pathway may be involved in regulating
42
43 pluripotency factor expression in malignant germ cells, but manipulation of the pathway does not appear
44
45 to affect cisplatin-sensitivity or tumour cell proliferation.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 **Key words**

2
3
4 Nodal and Activin signalling

5
6 Expression of pluripotency factors

7
8 GCNIS

9
10
11 Testicular cancer

12
13 Cisplatin-sensitivity

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

Background

Testicular germ cell tumours (TGCTs) in young adults originate from a common precursor, germ cell neoplasia *in situ* (GCNIS, previously known as carcinoma *in situ*) [1-3]. GCNIS cells are considered to be transformed gonocytes that have failed to differentiate to pre-spermatogonia during fetal testis development, most likely as a consequence of altered signalling from the somatic niche [3]. The arrest of gonocyte maturation is regarded as the initial step in the testicular cancer pathogenesis and results in the presence of a sub-population of cells with retained expression of pluripotency factors in postnatal life [1-3].

Around puberty, the hormonal changes and re-organisation of the testes required to support spermatogenesis are hypothesised to promote increased proliferation and gain of invasive capacity of the GCNIS cells, resulting subsequently in formation of TGCTs. The two main types of TGCTs are seminoma (SEM) and non-seminoma (non-SEM), where the latter may contain undifferentiated embryonal carcinoma (EC) as well as the more differentiated yolk sac tumour (YST), choriocarcinoma (CHC) and teratoma (TER) components [4].

Treatment of TGCTs depends on the tumour subtype and stage, with generally excellent cure rates even for advanced disease. In most cases, orchiectomy followed by surveillance is sufficient, but TGCTs that metastasise (most often non-SEMs) may require a combination of surgery, chemotherapy and in a few cases radiation therapy [5]. TGCTs are generally highly sensitive to cisplatin-based chemotherapy presumably due to their fetal germ cell origin, but the mechanisms underlying this overall high cisplatin-sensitivity of TGCTs and occasional treatment resistance, are not understood in detail [6, 7]. An association between the embryonic phenotype of the majority of TGCTs and high cisplatin-sensitivity has been established, whereas the differentiated types of TGCTs, such as TER and CHC, are generally considered more resistant to treatment [8]. The relationship between expression of pluripotency factors and cisplatin-sensitivity has also been examined in a TGCT-derived EC cell line, in which loss of pluripotency factor expression by siRNA-mediated knockdown of *OCT4*, resulted in decreased sensitivity to cisplatin [9].

1 Moreover, treatment with retinoic acid to induce differentiation of the EC-derived NTera2 cell line along
2
3 the neuroectodermal lineage, resulted in decreased expression of the pluripotency factor OCT4 and
4
5 increased cisplatin-resistance [10-12], thus supporting the association between pluripotency factor
6
7 expression and cisplatin-sensitivity. Although cisplatin-based chemotherapy has provided high cure rates
8
9 for TGCTs, the treatment regimen is associated with long-term complications, including cardiovascular side
10
11 effects and infertility as well as relapse [5, 13]. Therefore, optimisation of the current treatment regimen
12
13 would be beneficial.
14
15
16
17
18
19

20 Despite the general understanding that expression of pluripotency factors is a hallmark of GCNIS and the
21
22 majority of TGCTs, the underlying molecular mechanisms responsible for the maintenance or re-activation
23
24 of pluripotency factor expression in these malignant germ cells are not well understood. Several
25
26 independent studies have implicated the Nodal signalling pathway in the pathogenesis of TGCTs [12, 14-
27
28 19]. Recently, we found that stimulation of the Nodal pathway in human fetal testes prolonged the
29
30 expression of OCT4 in gonocytes, thus directly implicating the pathway in the regulation of the gonocyte to
31
32 pre-spermatogonia transition during human fetal testis development [19] and involvement in regulating
33
34 pluripotency factor expression in fetal germ cells (reviewed in [20]). Furthermore, high expression of the
35
36 Nodal signalling factors *NODAL*, *LEFTY1* and *CRIPTO* has been reported in GCNIS cells, TGCTs and TGCT-
37
38 derived cell lines [12, 16, 17], and several studies have found co-expression of Nodal signalling and
39
40 pluripotency factors in NTera2 cells [12, 15]. Also, heterogeneous expression of the co-receptor *CRIPTO* was
41
42 found in NTera2 cells, with highest expression in the subpopulation of cells displaying the most tumorigenic
43
44 potential [15].
45
46
47
48
49
50
51
52

53 Nodal and Activin signal through essentially the same receptors, including the activin receptors type 1
54
55 (*Alk4/7*) and type 2 (*ActRIIA/IIB*). An important difference is that Nodal also requires the presence of the co-
56
57 receptor *Cripto* for signal transduction. Among the target genes of the Nodal pathway are *Nodal* itself and
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

the endogenous inhibitor *Lefty1/2*, which blocks the formation of the receptor complex by binding Nodal directly or by interacting with Cripto [21]. The endogenous inhibitor of Activin signalling is Follistatin, which binds directly to Activin to inhibit this pathway. In recent years, Nodal signalling has emerged as a promising therapeutic target due to its aberrant re-expression and signalling in various types of cancers, including breast cancer, melanoma, prostate cancer and pancreatic cancer [22-26]. Interestingly, we found that simultaneous inhibition of Nodal and Activin signalling resulted in an almost complete loss of gonocytes in human fetal testes [19]. Despite the implication of the Nodal signalling pathway in the pathogenesis of TGCTs, the mechanisms by which this signalling pathway is dysregulated in TGCTs remain to be elucidated. Therefore, we hypothesised that dysregulation of the Nodal signalling pathway is involved in the regulation of pluripotency factor expression and proliferation in malignant germ cells, and thus is associated with the characteristically high cisplatin-sensitivity of these cells.

1 **Methods**

2
3
4 The aim of the this study was to investigate the involvement of Nodal signalling in the regulation of
5 pluripotency factor expression, tumour cell proliferation and cisplatin-sensitivity in malignant germ cells by
6 experimental manipulation of this pathway in NTera2 cells *in vitro* and in a xenograft model as well as in
7 primary *ex vivo* cultures of adult testis tissue containing GCNIS cells.
8
9
10
11
12
13
14
15

16 **Human tissue sample collection and preparation**

17
18 Tissue samples used in this study were collected according to the Helsinki Declaration following approval by
19 the regional ethics committee (H-1-2012-007) and all patients gave their informed written and oral consent
20 prior to surgery. Testicular tissue with and without presence of GCNIS cells and testicular tumour samples
21 were obtained after orchiectomy for testicular cancer. Tissue samples were transported to the Pathology
22 Department (Copenhagen University Hospital) immediately after the orchiectomy where a pathologist
23 examined the testes, dividing it into tumour and macroscopically normal areas. The majority of the tissue
24 was used for diagnostic evaluation, while the remaining tissue was allocated to research and either snap-
25 frozen and stored at -80°C or fixed in formalin or Bouin's fixative. Alternatively, the collected testis tissues
26 were placed in cell culture media, immediately transported to the laboratory and set up in *ex vivo* culture
27 as described below. Testis specimens included samples of 'normal testis (NT)', samples containing GCNIS,
28 SEM, EC and TER (only used for gene expression analysis). Tissue fragments with normal morphology and
29 containing complete spermatogenesis without the presence of malignant germ cells were used as 'normal
30 adult testis' controls. All tissue samples were evaluated by an experienced pathologist using a panel of
31 immunohistochemical markers to characterise GCNIS cells and tumour subtypes, including placental-like
32 alkaline phosphatase (PLAP), podoplanin (PDPN/D2-40), OCT4 (POU5F1), and (for non-SEMs only) also
33 alpha-fetoprotein (AFP) and beta-choriogonadotropin (hCG) [27]. Frozen tissue specimens used for gene
34 expression analysis were sectioned from each end of the tissue fragment and evaluated using
35 immunohistochemistry to confirm the histological tumour subtype prior to RNA extraction.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Immunohistochemistry

Immunohistochemistry on formalin-fixed tissue was performed as previously described in detail [28]. The fixed tissue samples were dehydrated, paraffin-embedded and sectioned (4 μm). Immunohistochemistry on Bouin's fluid-fixed testicular tissue, TGCT samples and formalin-fixed Ntera2 cells grown on glass slides was conducted using a pressure cooker for antigen-retrieval as previously described [19]. Visualisation was performed with ImmPACT DAB peroxidase substrate (Vector Laboratories, Burlingame, CA, US). Primary antibodies, dilutions and retrieval buffers are listed in Table 1. All sections were counterstained with Mayer's haematoxylin before mounting with Aquatex (Merck, Kenilworth, NJ, US). Positive and negative controls were included for both protocols. Positive control samples included tissue/cells known to express the studied protein, including OCT4 (adult testes with GCNIS cells), NODAL, CRIPTO, LEFTY (mouse fetal testes and EC tumours), cPARP (adult testes, nuclease-treated) and BrdU (fetal testis culture, BrdU-treated). Negative controls were processed with the primary antibody replaced by the dilution buffer alone with none of the negative controls exhibiting any staining. Sections were evaluated using a Nikon Microphot-FXA microscope, subsequently scanned using a Nano-Zoomer 2.0 HT (Hamamatsu Photonics, Herrsching am Ammersee, Germany) and analysed using the software NDPview version 1.2.36 (Hamamatsu Photonics).

Quantitative RT-PCR

Quantitative RT-PCR (RT-qPCR) was performed as previously described [19] using the QuantStudio 3 Real-Time PCR System (Thermo Fisher, Rochester, NY, US). In brief, mRNA was extracted from frozen tissue specimens and cell lines using the RNAqueous Micro Kit (Ambion, Austin, TX, US) or Nucleospin RNA purification kit (Macherey-Nagel, Düren, Germany), respectively. cDNA was synthesised using 1 μg mRNA, a dT20 primer and random hexamers, resulting in 100 μl cDNA, with 1 μl cDNA used for each RT-qPCR reaction. Gene expression was analysed using pre-specific primers (Table 2) designed to span intron-exon boundaries. All primers had previously been verified (Eurofins Genomics, Ebersberg, Germany). cDNA used

1 for gene expression analysis in this study have also been used in a previous study [29]. RT-qPCR analyses
2
3 were measured as duplicates and triplicates for frozen tissue specimens and cell line RNA extracts,
4
5 respectively, using Brilliant II SYBR Green qPCR Master mix (Aligent technologies, Santa Clare, CA, US). The
6
7 thermal cycling programme was: 95°C for 15 min followed 40 cycles of 95°C for 15 sec and 62°C for 1 min.
8
9 Changes in gene expression were examined using the $2^{-\Delta\Delta Ct}$ method [30]. Expression levels were
10
11 normalised to *RPS20* or *RPS29* and calculated as a ratio with NT samples or vehicle controls set to 1.
12
13
14
15
16
17

18 **Culture of TGCT-derived NTera2 cell line**

19
20 The TGCT-derived embryonal carcinoma cell line NTera2 was a kind gift from Professor Peter Andrews
21
22 (University of Sheffield, UK) [31]. The NTera2 cells were cultured according to standard culture conditions.
23
24 In brief, cells were cultured in DMEM supplemented with 10% fetal bovine serum, glutamine (58.5 mg/ml),
25
26 penicillin (100 U/ml) and streptomycin (100 mg/ml) at 37°C in a 5% CO₂ atmosphere. Cell media and
27
28 reagents were from Gibco (Invitrogen, Carlsbad, CA, US). For gene expression analyses and co-treatment
29
30 experiments, the ALK4/5/7 inhibitor SB431542 [32] that simultaneously inhibits Nodal and Activin signalling
31
32 (40 µM, 20 µM, 10 µM, 4 µM), recombinant Nodal (50 ng/ml), recombinant Activin (50 ng/ml), recombinant
33
34 Lefty (100 ng/ml), recombinant Follistatin (100 ng/ml) and cisplatin (1 and 5 µM, stock solution 1 mg/ml
35
36 dissolved in 0.9% NaCl from EberwePharma, Unterach am Attersee, Austria) were added to the media.
37
38 SB431542 were dissolved in DMSO, while Nodal, Activin, Lefty and Follistatin were dissolved in PBS with
39
40 0.1% BSA or 4 mM HCl, 0.1% BSA in PBS. The recombinant proteins were purchased from R&D systems
41
42 (Minneapolis, MN, US), while SB431542 was purchased from Sigma Aldrich (St. Louis, MO, US). Cells were
43
44 plated in 25 cm² flasks (Nunc, Thermo Fisher), incubated overnight before treatment was initiated and
45
46 during the treatment period cells were split every 48 h with complete media change. Half of the cells were
47
48 plated in new 25 cm² flasks and the other half were collected for analysis. NTera2 cells used for
49
50 immunohistochemical analysis were grown on glass slides (Nunc™ Lab-Tek™ II Chamber Slide™ System) for
51
52 48 h followed by fixation in 4% formalin. Slides were stored at 4°C until further analysis.
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Cell proliferation assay

Proliferation of NTERA2 cells was determined after 24 h and 48 h treatment with SB431542, and after co-treatments with SB431542 or recombinant Lefty and cisplatin. Proliferation was evaluated using the WST-1 assay according to the manufacturer's instructions (Roche, Basel, Schweiz). 10,000 NTERA2 cells were seeded into a 96-well plate with sixteen replicates of each sample and incubated overnight. Cells were then treated with SB431542 (5 μ M, 10 μ M and 20 μ M) or vehicle control (0.1% DMSO) for 24 h and 48 h. To assess proliferation, 1:10 WST-1 dye (Roche) in serum-free DMEM was added to the cells for 2 h before absorbance was measured at 450 nm and 630 nm using a FLUOstar Omega microplate reader (BMG Labtech, Ortenberg, Germany) or an Epoch Microplate Spectrophotometer (Biotek, Brøndby, Denmark). For co-treatments, 4,000 cells/well were plated into 96-well plates with eight replicates of each sample and allowed to attach for 6 h. Treatment with SB431542 (5 μ M and 20 μ M), recombinant Lefty (100 ng/ml) or vehicle control (0.1% DMSO) was then initiated for 48 h. Subsequently, media were removed and replaced with media containing cisplatin (1 μ M and 5 μ M) or 0.9% NaCl for 48 h. Cell proliferation was assessed with the WST-1 assay as described above.

***Ex vivo* culture of adult human testis samples**

Testis tissue samples (NT/GCNIS) obtained from orchiectomised testicular cancer patients (described above) were set up *ex vivo* in hanging drop cultures as described previously [33], with a few modifications. In brief, hanging drops were set up using 40 μ l drops of culture medium \pm treatment with addition of a single testicular fragment (1 mm³) per drop and complete media change every 48 h. Nine tissue fragments were set up for each treatment. Media composition was: DMEM:F12, penicillin (100 U/ml), streptomycin (100 mg/ml), insulin, transferrin, selenium (x1) and 10% fetal bovine serum. Media and supplements were all purchased from Gibco. Cultures were incubated for 48 h and 4 days at 34°C in 5% CO₂. 6 h before the end

1 of the culture period, the testis pieces were incubated with BrdU-labelling reagent (Invitrogen).
2
3 Subsequently, tissue fragments were fixed in 4% formalin.
4
5
6
7

8 **siRNA-mediated knockdown of *CRIPTO* expression**

9

10 siRNA-mediated knockdown was carried out as previously described [12]. siRNA specific for *CRIPTO* (TDGF1-
11 HSS144243, Invitrogen), a non-specific siRNA control (MISSION siRNA Universal Negative Control, SICOO1,
12 Sigma Aldrich) and transfection agent RNAiMAX Lipofectamine (Life Technologies, Carlsbad, CA, US) was
13 used. In brief, 1×10^6 NTERA2 cells were seeded into a 6-well plate and at the time of transfection cells were
14 approximately 60-70% confluent. A concentration of 50 nM siRNA was used. 24 h after transfection, cells
15 were re-plated into a 96-well plate (4,000 cells/well) or cultured in T-25 cm² flasks for RNA extractions.
16 After 48 h, media was removed from the 96-well plate and replaced with media containing cisplatin (1 μ M
17 or 5 μ M) or 0.9% NaCl for 48 h. Cell proliferation was determined by the WST-1 assay as described above.
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 **Establishment of NTERA2 xenografts and treatments in NMRI nude mice**

33

34 The establishment and experiments conducted in this model were set up by technicians at Pipeline Biotech
35 A/S (Trige, Denmark). Animal experiments were conducted in compliance with the Danish Animal
36 Experiments Inspectorate (license number 2011/561-1956) and conducted as previously described [10, 34],
37 with few modifications. Briefly, 30 NMRI male mice (Fox^{nu1}) aged 6-8 weeks (Janvier labs, Le Genest-Saint-
38 Isle, France) were injected once with 2×10^6 NTERA2 cells into each flank. When the tumours reached an
39 approximate size of 150 mm³, the mice were randomly allocated into three treatment groups of ten
40 animals; treatment group 1, cisplatin (6 mg/kg i.p. once during experiment), treatment group 2, cisplatin +
41 SB431542 (6 mg/kg cisplatin i.p. once during experiment and 10 mg/kg SB431542 i.p. 3 times weekly) and
42 treatment group 3, vehicle (10 mg/kg DMSO i.p. 3 times weekly). Treatment groups 1 and 3 were also used
43 in a separate study to reduce the total number of animals included (Lorenzen *et al.*, unpublished). Body
44 weight and tumour volume were measured 3 times weekly throughout the experimental period of 14 days.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Tumour volume was calculated as: tumour volume = length × width × ½ width. At the end of the
2
3 experiment mice were euthanized by inhalation of CO₂ followed by cervical dislocation. The mice were
4
5 caged in European standard cages type II with Jeluxyl HW 300/500 bedding and the housing and changing
6
7 system was designed to assure that MPF-status was preserved during the study. The air was exchanged
8
9 approximately 12 times per hour and temperature was kept between 20°C and 24°C (controlled via the
10
11 ambient ventilation system). Light cycle was 12-hour dark and 12-hour light. During the entire experimental
12
13 period mice were fed *ad libitum* with Standard diet (Altromin 1234, 600 IE D3/kg diet; Altromin, Lage,
14
15 Germany) and UV-sterilised water were administered *ad libitum*. All animals were inspected on a daily basis
16
17 for their general condition. Any animal showing clinical signs of moderate pain or distress, any degree of
18
19 suffering or clinical signs that exceed the limits of the study specific end-point would have been humanely
20
21 euthanized according to the European and Danish legislation on animals in experimental studies.
22
23
24
25
26
27
28

29 **Statistical analysis**

30
31 Statistical analysis was performed using the Software GraphPad Prism 8 (San Diego, CA, US). Differences in
32
33 gene expression and cell proliferation were tested using a two-tailed Student's t-test, while differences in
34
35 tumour growth were tested using a one-way ANOVA with Bonferroni correction. Statistically significant
36
37 differences are indicated as * P<0.05, ** P<0.01 and *** P<0.001. The number of replicates in each
38
39 experimental set-up and statistical significance are specified in figure legends.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Results

Expression of Nodal signalling factors in normal testis, GCNIS, testicular tumours and NTera2 cells

The expression levels of *NODAL*, *CRIPTO* and *LEFTY1* were initially investigated by RT-qPCR in tissue from adult testis samples with full spermatogenesis and no presence of malignant germ cells (hereafter termed 'normal testis' (NT)), samples containing pre-invasive GCNIS cells in the majority of tubules (GCNIS), seminoma tumour (SEM), embryonal carcinoma tumour (EC) and teratoma tumour (TER). *OCT4* (*POU5F1*) and *NANOG* were included to verify the neoplastic content in GCNIS, SEM and EC samples. Overall, the investigated Nodal pathway genes were all expressed in the included samples, but at very different levels (Supplementary Fig. 1a). In GCNIS, SEM and EC, the expression of *OCT4* (GCNIS, SEM, $P < 0.05$; EC, $P < 0.001$) and *NANOG* (all $P < 0.05$) was significantly increased compared to NT, verifying the neoplastic content within these samples. The expression of Nodal signalling factors *NODAL* ($P < 0.001$), *CRIPTO* ($P < 0.05$) and *LEFTY1* ($P < 0.001$) was significantly higher in EC samples compared to NT as well as GCNIS, SEM and TER.

Protein expression of *NODAL*, *CRIPTO* and *LEFTY* (antibody detects both *LEFTY1* and *LEFTY2*) was examined by immunohistochemistry in serial sections of NT, GCNIS, SEM and EC. *OCT4* was included as a marker of malignant germ cells, and was detected in GCNIS, SEM and EC, but not in NT which is in accordance with the expected expression pattern (Supplementary Fig. 1b). *NODAL*, *CRIPTO* and *LEFTY* were expressed in all investigated samples, except NT. The expression of all three Nodal pathway proteins was more pronounced in EC compared to GCNIS and SEM, with co-expression of all three proteins in *OCT4*⁺ EC cells. Interestingly, the expression of *NODAL*, *CRIPTO* and *LEFTY* was found only in a sub-population of GCNIS cells and expression in these cells was low. Additionally, the expression pattern of *NODAL*, *CRIPTO*, *LEFTY* and *OCT4* was also examined in the EC-derived NTera2 cell line (Supplementary Fig. 1c). Noticeably, *CRIPTO* was strongly expressed in the nuclei in addition to the expected cytoplasmic/membranous expression. *NODAL* was expressed in the cytoplasm, whereas *LEFTY* appeared to be present between adjacent NTera2 cells, possibly reflecting secretion from the cells.

1
2
3
4 **Effects of simultaneous inhibition of Nodal and Activin signalling on proliferation and transcriptional**
5
6 **expression in NTera2 cells**

7
8 In order to investigate the effects of inhibiting Nodal and Activin signalling on proliferation of NTera2 cells,
9
10 treatment experiments with the ALK4/5/7 inhibitor SB431542 [32], were conducted. Treatment with 20
11
12 μM , 10 μM and 5 μM SB431542 had no significant effect ($P>0.05$) on proliferation of NTera2 cells after 24 h
13
14 or 48 h (Fig. 1a-b). In contrast, treatment with SB431542 (40 μM , 20 μM and 4 μM) for 48 h resulted in
15
16 significantly lower expression of pluripotency factors *OCT4* (40 μM and 20 μM , $P<0.01$; 4 μM , $P<0.05$) and
17
18 *NANOG* ($P<0.001$) as well as *NODAL*, *CRIPTO* and *LEFTY1* (all $P<0.001$) in NTera2 cells (Fig. 1c). After 7 days
19
20 of treatment with SB431542 (40 μM , 20 μM and 4 μM), expression of all investigated genes remained
21
22 significantly reduced (Fig. 1d).
23
24
25
26
27
28
29

30 **Effects of manipulating Nodal and Activin signalling separately on the transcriptional expression pattern**
31
32 **in NTera2 cells and *ex vivo* cultures of adult testis tissue**

33
34 To separate the effects of inhibiting or stimulating Nodal and Activin signalling pathways individually, a
35
36 series of treatment experiments were performed in the NTera2 cell line. The Nodal pathway was stimulated
37
38 by treatment with recombinant Nodal (50 ng/ml) and inhibited by treatment with recombinant Lefty (100
39
40 ng/ml). Nodal treatment for 48 h resulted in a significant upregulation of *OCT4* ($P<0.05$) and *NANOG*
41
42 ($P<0.01$) as well as *NODAL* ($P<0.001$), *CRIPTO* ($P<0.01$) and *LEFTY1* ($P<0.001$) (Fig. 2a). The expression of
43
44 *OCT4* and *CRIPTO* (both $P<0.01$) remained upregulated after 7 days of treatment with recombinant Nodal
45
46 (Fig. 2b). In contrast, Lefty treatment for 48 h significantly reduced the expression level of all investigated
47
48 genes; *OCT4* ($P<0.05$), *NODAL* ($P<0.05$), *NANOG* ($P<0.01$), *CRIPTO* ($P<0.01$) and *LEFTY1* ($P<0.001$) (Fig. 2a).
49
50
51 The expression of *OCT4* ($P<0.01$), *NANOG* ($P<0.001$), *NODAL* ($P<0.01$), *CRIPTO* ($P<0.01$) and *LEFTY1*
52
53 ($P<0.001$) continued to be downregulated following Lefty treatment for 7 days (Fig. 2b). The Activin
54
55 pathway was stimulated using recombinant Activin A (50 ng/ml) and inhibited using recombinant Follistatin
56
57
58
59
60
61
62
63
64
65

1 (100 ng/ml). Activin treatment resulted in significantly higher expression of *NANOG* ($P<0.05$) and *LEFTY1*
2
3 (48 h, $P<0.05$; 7 days, $P<0.01$) at both 48 h and 7 days (Fig. 2c-d), with increased expression of *CRIPTO*
4
5 ($P<0.05$) also after 48 h. Follistatin treatment increased only the expression of *NANOG* ($P<0.05$) after 48 h.
6
7
8
9

10 To examine the effects of manipulating Nodal and Activin signalling in malignant germ cells preserved
11 within their somatic niche, the effects of SB431542, recombinant Nodal and Activin A were investigated in
12 cultures of primary testis tissue from testicular cancer patients (Fig. 3 and Fig. 4). Tissue containing tubules
13 with GCNIS cells (located adjacent to the TGCT tumour in the orchiectomised testis) from three patients
14 was cultured *ex vivo* for 48 h (Fig. 3) and 4 days (Fig. 4). None of the treatments significantly affected
15 ($P>0.05$) proliferation ($\text{BrdU}^+/\text{mm}^2$), apoptosis ($\text{cPARP}^+/\text{mm}^2$) or number of GCNIS cells ($\text{OCT4}^+/\text{mm}^2$)
16 compared to the vehicle controls after 48 h (Fig. 3b-e) or 4 days (Fig. 4b-d).
17
18
19
20
21
22
23
24
25
26
27
28

29 **Effects of pharmaceutical inhibition of Nodal and Activin signalling on cisplatin-sensitivity in NTera2 cells**

30 To determine whether co-treatment with inhibitors of the Nodal signalling pathway affects cisplatin-
31 sensitivity, NTera2 cells were treated with SB431542 (5 μM and 20 μM) or recombinant Lefty (100 ng/ml)
32 for 48 h followed by 48 h of cisplatin treatment (1 μM and 5 μM). Subsequently, effects on cell proliferation
33 was assessed. Co-treatments were conducted in three independent experiments, with similar results
34 obtained between the experiments (Fig. 5a). Overall, initial exposure to SB431542 or Lefty followed by
35 cisplatin treatment did not affect the cisplatin-sensitivity in the NTera2 cells. However, co-treatment with
36 20 μM SB431542 and 1 μM cisplatin significantly increased ($P<0.05$) proliferation compared to cells treated
37 with 1 μM cisplatin only, indicating that the cells were less sensitive to the cisplatin treatment (Fig. 5b).
38
39 Generally, there was a tendency towards reduced cisplatin-sensitivity when cells were co-treated with
40 SB431542 and cisplatin regardless of the doses used, although for most combinations of doses this was not
41 statistically significant ($P>0.05$).
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Effects of siRNA-mediated knockdown of *CRIPTO* expression on cisplatin-sensitivity in NTera2 cells

In order to examine whether the tendency towards reduced cisplatin-sensitivity found after inhibition of Nodal signalling (with SB431542) could be verified, the effect of *CRIPTO* knockdown on cisplatin-sensitivity was examined. Expression of the co-receptor *CRIPTO*, obligate for Nodal signalling, was knocked down in NTera2 cells by a siRNA approach. Subsequently, NTera2 cells were treated with cisplatin (1 μ M and 5 μ M) for 48 h and cell proliferation was assessed. The expression of *CRIPTO* was significantly reduced ($P < 0.05$) upon transfection with siCRIPTO compared to the siCTRL (Fig. 6a-b) in all individual experiments and when combined. Despite the significant reduction in *CRIPTO* expression ($P < 0.05$), no effect on cisplatin-sensitivity was found in the NTera2 cells when compared to the siCTRL-transfected NTera2 cells treated with cisplatin (Fig. 6c-d).

Effects of simultaneous inhibition of Nodal and Activin signalling on cisplatin-sensitivity in a NTera2

xenograft mouse model

Simultaneous inhibition of Nodal and Activin signalling by SB431542 treatment in combination with cisplatin treatment was subsequently investigated in an NTera2 xenograft mouse model. NTera2 cells were injected into the flanks of nude mice and after the development of tumours, treatment was initiated. The animals were treated with either cisplatin alone, a combination of cisplatin + SB431542 or vehicle control. None of the animals exhibited observable negative effects of the experimental procedure or treatments. In the vehicle-treated control mice, tumour burden continued to increase throughout the experimental period (Fig. 7), while in mice treated with cisplatin alone and cisplatin + SB431542, the tumour size was significantly reduced ($P < 0.01$ and $P < 0.001$) compared to the vehicle controls already 3 days after the treatments were initiated. However, no significant difference ($P > 0.05$) in tumour size was found between mice treated with cisplatin alone and cisplatin + SB431542 at any of the evaluated time-point (Fig. 7).

Discussion

In the present study, we found high expression of the Nodal signalling factors in undifferentiated types of TGCTs and our results suggests that the Nodal pathway may be involved in the regulation of pluripotency factor expression in malignant germ cells. However, targeting Nodal signalling in the EC-derived NTera2 cell line by several different experimental approaches did not affect proliferation of the malignant germ cells or result in any pronounced effects on cisplatin-sensitivity, indicating that the Nodal pathway may not represent a promising clinical target to augment the effect of current chemotherapy regimens in testicular cancer patients.

NODAL, CRIPTO and LEFTY1/2 were expressed at transcript and protein levels in GCNIS cells and the undifferentiated TGCTs, SEM and EC. The most pronounced expression of all Nodal pathway factors was found in EC and co-expressed in OCT4⁺ cells. In accordance with previous studies [14, 16, 18], the expression of Nodal factors in 'normal' testis without malignant cells was low/absent, suggesting maintenance of Nodal factor expression in GCNIS and/or re-activation in malignant germ cells. Additionally, the overall expression of the Nodal factors at both gene and protein levels in GCNIS and SEM was lower compared to EC which is in accordance with a previous study [18]. Interestingly, the protein expression of the Nodal pathway factors was less pronounced in GCNIS cells compared to EC but also to some extent SEM, which supports the notion that Nodal signalling components might be maintained only at low levels in GCNIS cells and are upregulated in the invasive tumours, although it remains to be determined whether the Nodal pathway is involved in the transition from GCNIS to EC/(SEM). The observed high expression of LEFTY1/2 in undifferentiated TGCTs, indicates that the inhibitory feedback mechanism on Nodal signalling may not be dysregulated in TGCTs, despite a previous study suggested this based on the reported low expression of *LEFTY1* in EC [16].

1 The Nodal signalling factors were all expressed in the NTera2 cell line, hence we used it as a model to
2
3 examine effects of manipulating Nodal signalling in TGCTs. Simultaneous inhibition of Nodal and Activin
4
5 pathways did not affect proliferation in NTera2 cells or in GCNIS cells in *ex vivo* cultured testis samples.
6
7 Since Nodal and Activin signalling have been implicated in germ cell survival in both human and mouse fetal
8
9 testes [19, 35], this may indicate a difference between normal fetal gonocytes and malignant germ cells,
10
11 although it is important to consider that in contrast to normal fetal germ cells, malignant TGCTs have
12
13 acquired features allowing them to survive outside of their normal niche. In the NTera2 cells, simultaneous
14
15 inhibition of Nodal and Activin signalling resulted in reduced expression of the investigated pluripotency
16
17 factors and Nodal pathway genes, and after separating the effects of Nodal and Activin signalling pathways
18
19 it was evident that the Nodal pathway was responsible for the majority of observed effects. Additionally,
20
21 the opposing effects observed after stimulating and inhibiting Nodal signalling, suggest that the pathway
22
23 may be involved in the regulation of pluripotency factor expression in malignant germ cells. These results
24
25 are in accordance with the reported involvement of Nodal signalling in regulating pluripotency factor
26
27 expression in human fetal testes [19], mouse fetal testes [16, 36, 37] and human embryonic stem cells [38].
28
29 However, manipulation of Nodal and Activin signalling in *ex vivo* cultures of GCNIS-containing tissue (48 h
30
31 and 4 days) did not overall affect the number of OCT4⁺ GCNIS cells, although in one patient sample an
32
33 increased number of OCT4⁺ GCNIS cells was observed following treatment with Nodal and Activin (48 h
34
35 and Nodal (4 days). The different responses between patient samples as well as the relative short-term
36
37 culture periods used in this study, suggest that additional studies examining the effects of stimulated
38
39 Nodal/Activin signalling on GCNIS cells may be relevant. Importantly, the overall low number of apoptotic
40
41 germ cells and the presence of proliferating cells in the cultured tissue samples, suggest that the tissue was
42
43 supported by the culture approach and that the selected treatment doses were not toxic. However, given
44
45 the high variation in the tissue, which is expected in testicular cancer patients [33], minor effects of
46
47 treatments can be difficult to detect using this experimental approach.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Aberrant re-activation of Nodal signalling has been reported in various types of cancers, including cancer
2 stem cells which also express pluripotency factors, and several studies have shown that inhibition of
3 Nodal/(Activin) signalling reduces the tumorigenic potential both *in vitro* and in cancer mouse models [22-
4 26]. Additionally, combined treatment with the SB431542 inhibitor and chemotherapy (gemcitabine)
5 abolished tumours in a pancreatic cancer mouse model and resulted in complete survival of mice in this
6 treatment group [24]. Moreover, given the almost complete germ cell loss following SB431542 treatment
7 of human fetal testes, we examined whether co-treatment with this inhibitor could augment cisplatin-
8 sensitivity in NTERA2 cells. Overall, we did not observe pronounced effects on cisplatin-sensitivity following
9 inhibition of Nodal signalling *in vitro* or in the xenograft model, except tendencies toward reduced cisplatin-
10 sensitivity after *in vitro* pharmaceutical inhibition of Nodal/Activin signalling and siRNA-mediated
11 knockdown of the obligate co-receptor *CRIPTO*. *In vitro* treatment with recombinant Lefty to inhibit only
12 Nodal signalling did not result in reduced cisplatin-sensitivity (or showed tendencies in this direction),
13 which could reflect the different levels at which inhibitory molecules and siRNA-mediated knockdown
14 functions [39]. Additionally, the slightly increased cisplatin-resistance observed following blockage of both
15 Nodal and Activin signalling (using the high dose of SB431542), but not after specific inhibition of Nodal
16 signalling, could indicate some redundancy between the Nodal and Activin pathways. We speculate that
17 inhibition of Nodal signalling promotes downregulation of pluripotency factor expression in the malignant
18 germ cells driving them towards a more differentiated phenotype, which is associated with reduced
19 cisplatin-sensitivity [8-12]. However, since both ECs (high Nodal expression) and SEMs (low Nodal
20 expression) are highly sensitive to cisplatin-based treatment [6, 7], this may explain why we did not find
21 pronounced effects on cisplatin-sensitivity upon manipulation of the Nodal signalling pathway. It has
22 previously been demonstrated that calcitriol treatment (active form of vitamin D) of NTERA2 cells resulted
23 in both decreased expression of pluripotency factors and augmented effects of cisplatin, while treatment of
24 NTERA2 with retinoic acid decreased the expression of pluripotency factors and reduced cisplatin-mediated
25 effects [10, 34]. This suggests that the relationship between pluripotency factor expression and cisplatin-
26

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

sensitivity in malignant germ cells is not completely understood and that further studies examining this would be relevant.

1 **Conclusions**

2
3
4 In conclusion, the Nodal signalling factors are highly expressed in the undifferentiated types of TGCTs and
5
6 may be involved in the regulation of pluripotency factor expression in malignant germ cells. In contrast to
7
8 several other types of cancers in which the Nodal pathway is also re-activated, inhibition of Nodal (and
9
10 Activin) signalling did not affect tumour cell proliferation or augment cisplatin-sensitivity in TGCTs *in vitro*
11
12 or in the xenograft model. Thus, the different response to the pharmaceutical pathway inhibitor SB431542
13
14 in TGCTs compared to human fetal germ cells, suggests that regulation or feedback mechanisms related to
15
16 the Nodal pathway may be altered in malignant germ cells, although additional studies are needed to
17
18 examine these mechanisms in more detail.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 **List of abbreviations**

2		
3		
4	CHC	Choriocarcinoma
5		
6	EC	Embryonal carcinoma
7		
8	GCNIS	Germ cell neoplasia <i>in situ</i>
9		
10	i.p.	Intraperitoneal injection
11		
12	Non-SEM	Non-seminoma
13		
14	NT	Normal testis
15		
16	SEM	Seminoma
17		
18	TER	Teratoma
19		
20	TGCTs	Testicular germ cell tumours
21		
22	YST	Yolk sac tumour
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		
61		
62		
63		
64		
65		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Declarations

Ethics approval and consent to participate

Ethical approval was obtained for collection of human testis samples from University Hospital of Copenhagen (Rigshospitalet), Copenhagen, Denmark (H-1-2012-007). Written and informed consent was obtained for the use of all tissues included in the study. Animal experiments were approved prior to the beginning of the study and were conducted by Pipeline Biotech in compliance with the Danish Animal Experiments Inspectorate (license number 2011/561-1956).

Consent for publication

The study involves the use of tissues from anonymised and non-identifiable patients.

Availability of data and materials

The data to support the findings of this study are available upon reasonable request from the corresponding author, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported in part by an ESPE Research Fellowship, sponsored by Novo Nordisk A/S to A. Jørgensen. Additional funding for this project was obtained from The Danish Cancer Society (Grant no: R72-A4335-13-S2, AJØ), The Erichssen Family Fund (AJØ), Dagmar Marshalls Fund (AJØ) and Aase & Ejnar Danielsens Fund (AJØ). The funders had no involvement in the design of the study or in collection, analysis, and interpretation of data as well as in writing the manuscript.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Author contributions

Conceived and designed the experiments: KHP, AJØ. Performed the experiments: KHP, JEN. Analysed the data: KHP, LJR, MBJ, RTM, AJU, ERDM, AJØ. Contributed reagents/materials/analysis tools and expertise: BGT, UNJ. Wrote the manuscript: KHP, AJØ. All authors approved the submitted version.

Acknowledgements

The authors wish to thank the technicians from the Department of Growth and Reproduction, especially the excellent help from Ana Ricci Nielsen, Camilla Tang Thomsen and Brian Vendelbo Hansen is gratefully acknowledged. We appreciate the help from staff at the Urology Department and Pathology Department in provision of testicular tissue.

References

- [1] Skakkebaek NE. Possible carcinoma-in-situ of the testis. *Lancet* (London, England) 1972;2:516–517.
[https://doi.org/10.1016/s0140-6736\(72\)91909-5](https://doi.org/10.1016/s0140-6736(72)91909-5)
- [2] Skakkebaek NE, Berthelsen JG, Giwercman A and Müller J. Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. *Int Journal of Androl* 1987;10:19–28. <https://doi.org/10.1111/j.1365-2605.1987.tb00161.x>
- [3] Rajpert-De Meyts E. Developmental model for the pathogenesis of testicular carcinoma in situ: Genetic and environmental aspects. *Hum Reprod Update* 2006;12:303–323.
<https://doi.org/10.1093/humupd/dmk006>
- [4] Ulbright TM, Amin MB, Balzer B, Berney DM, Epstein JI, Guo C, Idrees MT, Looijenga LHJ, Paner G, Rajpert-De Meyts E, Skakkebaek NE, Tickoo SK, Yilmaz A, and Oosterhuis JW, in *WHO Classification of Tumours of the Urinary System and Male Genital Organs*, 4th edn., ed. by H. Moch, P.A. Humphrey, T.M. Ulbright. Germ cell tumours (IARC Press, Lyon, 2016), 189–226.
- [5] Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MAS, and Bokemeyer C. Testicular germ cell tumours. *The Lancet* 2016;387:1762–1774. [https://doi.org/10.1016/S0140-6736\(15\)00991-5](https://doi.org/10.1016/S0140-6736(15)00991-5)
- [6] Jacobsen C and Honecker F. Cisplatin resistance in germ cell tumours: models and mechanisms. *Andrology* 2015;3:111–121. <https://doi.org/10.1111/andr.299>
- [7] Singh R, Fazal Z, Freemantle SJ, and Spinella MJ. Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors. *Cancer Drug Resist* (Alhambra, Calif.) 2019;2:580–594.

1 <https://dx.doi.org/10.20517%2Fcdr.2019.19>
2
3
4

5 [8] Oosterhuis JW and Looijenga LHJ. Human germ cell tumours from a developmental perspective.
6 Nature reviews Cancer 2019;19:522–537. <https://doi.org/10.1038/s41568-019-0178-9>
7
8
9

10
11
12 [9] Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H, and Schmoll HJ. Loss of Oct-3/4 expression
13 in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumor Biology
14 2006;27:71–83. <https://doi.org/10.1159/000092324>
15
16
17
18
19
20
21

22 [10] Jørgensen A, Blomberg Jensen M, Nielsen JE, Juul A, and Rajpert-De Meyts E. Influence of vitamin D
23 on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a Ntera2 xenograft
24 model. J Steroid Biochem Mol Biol 2013;136:238–46. <https://doi.org/10.1016/j.jsbmb.2012.10.008>
25
26
27
28
29
30

31 [11] Abada PB and Howell SB. Cisplatin induces resistance by triggering differentiation of testicular
32 embryonal carcinoma cells. PLoS ONE 2014;9:e87444.
33
34
35
36 <https://doi.org/10.1371/journal.pone.0087444>
37
38
39
40

41 [12] Rudolph C, Melau C, Nielsen JE, Vile Jensen K, Liu D, Pena-Diaz J, Rajpert-De Meyts E, Rasmussen LJ,
42 and Jørgensen A. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular
43 germ cell tumours. Cell Oncol 2017;40:341–355. <https://doi.org/10.1007/s13402-017-0326-8>
44
45
46
47
48
49
50

51 [13] Feldman DR, Bosl GJ, Sheinfeld J, and Motzer RJ. Medical treatment of advanced testicular cancer.
52 JAMA 2008;299:672–84. <https://doi.org/10.1001/jama.299.6.672>
53
54
55
56
57

58 [14] Baldassarre G, Romano A, Armenante F, Rambaldi M, Paoletti I, Sandomenico C, Pepe S, Staibano S,
59
60
61
62
63
64
65

1 Salvatore G, De Rosa G, Persico MG and Viglietto G. Expression of teratocarcinoma-derived growth
2 factor-1 (TDGF-1) in testis germ cell tumors and its effects on growth and differentiation of
3 embryonal carcinoma cell line NTERA2 / D1. *Oncogene* 1997;15:927–936.
4
5

6 <https://doi.org/10.1038/sj.onc.1201260>
7
8
9

- 10
11
12 [15] Watanabe K, Meyer MJ, Strizzi L, Lee JM, Gonzales M, Bianco C, Nagaoka T, Farid SS, Margaryan N,
13 Hendrix MJC, Vonderhaar BK and Salomon DS. Cripto-1 Is a Cell Surface Marker for a Tumorigenic,
14 Undifferentiated Subpopulation in Human Embryonal Carcinoma Cells. *Stem Cells* 2010;28:1303–
15 1314. <https://doi.org/10.1002/stem.463>
16
17
18
19

- 20
21
22 [16] Spiller CM, Feng CW, Jackson A, Gillis AJM, Rolland AD, Looijenga LHJ, Koopman P, and Bowles J.
23 Endogenous Nodal signaling regulates germ cell potency during mammalian testis development.
24 *Development* 2012;139:4123–4132. <https://doi.org/10.1242/dev.083006>
25
26
27
28
29

- 30
31
32 [17] Spiller CM, Gillis AJM, Burnet G, Stoop H, Koopman P, Bowles J and Looijenga LHJ. Cripto:
33 Expression, epigenetic regulation and potential diagnostic use in testicular germ cell tumors. *Mol*
34 *Oncol* 2015;30:1–12. <https://doi.org/10.1016/j.molonc.2015.11.003>
35
36
37
38
39

- 40
41
42 [18] Nettersheim D, Jostes S, Sharma R, Schneider S, Hofmann A, Ferreira HJ, Hoffmann P, Kristiansen G,
43 Esteller MB, and Schorle H. BMP Inhibition in Seminomas Initiates Acquisition of Pluripotency via
44 NODAL Signaling Resulting in Reprogramming to an Embryonal Carcinoma. *PLoS Genetics*
45 2015;11:1–26. <https://doi.org/10.1371/journal.pgen.1005415>
46
47
48
49
50

- 51
52
53 [19] Jørgensen A, Macdonald J, Nielsen JE, Kilcoyne KR, Perlman S, Lundvall L, Langhoff Thuesen L, Juul
54 Hare K, Frederiksen H, Andersson AM, Skakkebaek NE, Juul A, R. Sharpe M, Rajpert-De Meyts E and
55
56
57
58
59

1 Mitchell RT. Nodal Signaling Regulates Germ Cell Development and Establishment of Seminiferous
2
3 Cords in the Human Fetal Testis. Cell Reports 2018;25:1924–1937.e4.

4
5 <https://doi.org/10.1016/j.celrep.2018.10.064>
6
7
8
9

- 10 [20] Harpelunde Poulsen K and Jorgensen A. Role of Nodal signalling in testis development and initiation
11
12 of testicular cancer. Reproduction (Cambridge, England) 2019;158:R67-R77.

13
14 <https://doi.org/10.1530/REP-18-0641>
15
16
17
18
19

- 20 [21] Cheng SK, F. Olale, Brivanlou AH and Schier AF. Lefty blocks a subset of TGF β signals by antagonizing
21
22 EGF-CFC coreceptors. PLoS Biology 2004;2:e30. <https://dx.doi.org/10.1371%2Fjournal.pbio.0020030>
23
24
25
26

- 27 [22] Topczewska JM, Postovit LM, Margaryan NV, Sam A, Hess AR, Wheaton WW, Nickoloff BJ,
28
29 Topczewski J, and Hendrix MJC. Embryonic and tumorigenic pathways converge via Nodal signaling:
30
31 role in melanoma aggressiveness. Nat Med 2006;12:925–32. <https://doi.org/10.1038/nm1448>
32
33
34
35

- 36 [23] Lawrence MG, Margaryan NV, Loessner D, Collins A, Kerr KM, Turner M, Seftor EA, Stephens CR, Lai
37
38 J, APC BioResource, Postovit LM, Clements JA, and Hendrix MJC. Reactivation of embryonic nodal
39
40 signaling is associated with tumor progression and promotes the growth of prostate cancer cells.
41
42 Prostate 2011;71:1198–1209. <https://dx.doi.org/10.1002%2Fpros.21335>
43
44
45
46
47

- 48 [24] Lonardo E *et al.* Nodal/activin signaling drives self-renewal and tumorigenicity of pancreatic cancer
49
50 stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011;9:433–446.

51
52 <https://doi.org/10.1016/j.stem.2011.10.001>
53
54
55
56
57

- 58 [25] Strizzi L, Hardy KM, Margaryan NV, Hillman DW, Seftor EA, Chen B, Geiger XJ, Thompson EA, Lingle
59
60
61
62
63
64
65

1 WL, Andorfer CA, Perez EA, and Hendrix MJC. Potential for the embryonic morphogen Nodal as a
2 prognostic and predictive biomarker in breast cancer. *Breast Cancer Res* 2012;14:R75.
3

4
5
6 <https://doi.org/10.1186/bcr3185>
7

8
9
10 [26] Gong W, Sun B, Sun H, Zhao X, Zhang D, Liu T, Zhao N, Gu Q, Dong X and Liu F. Nodal signaling
11 activates the Smad2/3 pathway to regulate stem cell-like properties in breast cancer cells. *Am J*
12
13 *Cancer Res* 2017;7:503–517. PMID: 28401007
14
15

16
17
18
19
20 [27] Rajpert-De Meyts E, Nielsen JE, Skakkebaek NE and Almstrup K. Diagnostic markers for germ cell
21 neoplasms: from placental-like alkaline phosphatase to micro-RNAs. *Folia Histochem Cytobiol* 2015;
22
23 53(3):177-188. <https://doi.org/10.5603/FHC.a2015.0020>
24
25

26
27
28
29 [28] Jørgensen A, Nielsen JE, Blomberg Jensen M, Græm N and Rajpert-De Meyts E. Analysis of meiosis
30 regulators in human gonads: A sexually dimorphic spatio-temporal expression pattern suggests
31 involvement of DMRT1 in meiotic entry. *Mol Hum Reprod* 2012;18:523–534.
32
33

34
35
36 <https://doi.org/10.1093/molehr/gas030>
37
38

39
40
41 [29] Svingen T, Jørgensen A and Rajpert-De Meyts E. Validation of endogenous normalizing genes for
42 expression analyses in adult human testis and germ cell neoplasms. *Mol Hum Reprod* 2014;20:709–
43
44 718. <https://doi.org/10.1093/molehr/gau030>
45
46

47
48
49
50 [30] Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative
51 PCR and the 2^{-Delta Delta C(T)} Method. *Methods (San Diego, Calif.)* 2001;25:402–8.
52
53

54
55 <https://doi.org/10.1006/meth.2001.1262>
56
57
58
59
60
61
62
63
64
65

- 1 [31] Andrews PW, Damjanov I, Simon D, Banting GS, Carlin C, Dracopoli NC and Fogh J. Pluripotent
2 embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2:
3 Differentiation in vivo and in vitro. Lab Invest 1984;50:147-162.
4
5
6
7
8
9
10 [32] Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ and Hill CS. SB-431542 Is
11 a Potent and Specific Inhibitor of Transforming Growth Factor-beta Superfamily Type I Activin
12 Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65–74.
13
14 <https://doi.org/10.1124/mol.62.1.65>
15
16
17
18
19
20
21
22 [33] Jørgensen A, Young J, Nielsen JE, Joensen UN, Toft BG, Rajpert-De Meyts E and Loveland KL. Hanging
23 drop cultures of human testis and testis cancer samples: a model used to investigate activin
24 treatment effects in a preserved niche. Br J Cancer 2014;110:2604–2614.
25
26 <https://doi.org/10.1038/bjc.2014.160>
27
28
29
30
31
32
33
34 [34] Blomberg Jensen M, Jørgensen A, Nielsen JE, Steinmeyer A, Leffers H, Juul A, and Rajpert-De Meyts
35 E. Vitamin D Metabolism and Effects on Pluripotency Genes and Cell Differentiation in Testicular
36 Germ Cell Tumors In Vitro and In Vivo. Neoplasia 2012;14:952–963.
37
38 <https://dx.doi.org/10.1593%2Fneo.121164>
39
40
41
42
43
44
45
46 [35] Wu Q, Kanata K, Saba R, Deng CX, Hamada H and Saga Y. Nodal/activin signaling promotes male
47 germ cell fate and suppresses female programming in somatic cells. Development 2013;140:291–
48 300. <https://doi.org/10.1242/dev.087882>
49
50
51
52
53
54
55 [36] Miles DC, Wakeling SI, Stringer JM, van den Bergen JA, Wilhelm D, Sinclair AH and Western PS.
56 Signaling through the TGF Beta-Activin Receptors ALK4/5/7 Regulates Testis Formation and Male
57
58
59
60
61
62
63
64
65

1 Germ Cell Development. PLoS ONE 2013;8:1–16.

2
3 <https://dx.doi.org/10.1371%2Fjournal.pone.0054606>
4
5
6

7
8 [37] Tian-Zhong M, Bi C, Ying Z, Xia J, Cai-Ling P, Yun-Shan Z, Mei-Wen H and Yan-Ru N. Critical role of
9
10 Emx2 in the pluripotency - Differentiation transition in male gonocytes via regulation of
11
12 FGF9/NODAL pathway. Reproduction 2016;151:673–681. <https://doi.org/10.1530/REP-16-0022>
13
14
15

16
17 [38] Vallier L, Reynolds D and Pedersen RA. Nodal inhibits differentiation of human embryonic stem cells
18
19 along the neuroectodermal default pathway. Dev Biol 2004;275:403–421.
20
21
22 <https://doi.org/10.1016/j.ydbio.2004.08.031>
23
24
25

26
27 [39] Weiss WA, Taylor SS and Shokat KM. Recognizing and exploiting differences between RNAi and
28
29 small-molecule inhibitors. Nat Chem Biol 2007;3:739-744. [https://doi.org/10.1038/nchembio1207-](https://doi.org/10.1038/nchembio1207-739)
30
31 739
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 **Figure legends**
2
3

4 **Fig 1. Effects of simultaneously inhibiting Nodal and Activin signalling in the NTera2 cell line.** NTera2 cells
5 were treated with 20 μ M, 10 μ M and 5 μ M SB431542 for **a)** 24 h and **b)** 48 h followed by assessment of cell
6 proliferation. Experiments were set up with 16 replicates per treatment and repeated in three independent
7 experiments (n=3). Cell proliferation is set to 1 in the vehicle controls. Expression of pluripotency factors
8 (*OCT4*, *NANOG*) and Nodal pathway genes (*NODAL*, *CRIPTO*, *LEFTY1*) in NTera2 cells following **c)** 48 h and **d)**
9 7 days of treatment with SB431542 (40 μ M, 20 μ M and 4 μ M). *RPS20* was used as reference gene.
10 Expression level is set to 1 in the vehicle controls. Experiments were conducted in triplicates in three
11 independent experiments (n=3) and measured as technical triplicates. Values represent mean \pm SEM.
12 Significant difference compared to expression in vehicle control-treated cells, * P<0.05, ** P<0.01 and ***
13 P<0.001. Note logarithmic scale.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Fig 2. Effects of manipulating Nodal and Activin signalling separately in NTera2 cells.** Expression of
31 pluripotency factors (*OCT4*, *NANOG*) and Nodal signalling factors (*NODAL*, *CRIPTO*, *LEFTY1*) in NTera2 cells
32 following **a)** 48 h and **b)** 7 days of treatment with recombinant Nodal (50 ng/ml) and Lefty (100 ng/ml) and
33
34 **c)** 48 h and **d)** 7 days of treatment with Activin A (50 ng/ml) and Follistatin (100 ng/ml). *RPS20* was used as
35 reference gene. Expression level is set to 1 in the vehicle controls. Experiments were conducted in
36 triplicates in three independent experiments (n=3) and measured as technical triplicates. Values represent
37 mean \pm SEM. Significant difference compared to expression in vehicle control-treated cells, * P<0.05, **
38 P<0.01 and *** P<0.001. Note logarithmic scale.
39
40
41
42
43
44
45
46
47
48
49
50

51 **Fig 3. Effects of manipulating Nodal and Activin signalling in GCNIS cells cultured *ex vivo*.** **a)** Schematic
52 illustration of the experimental *ex vivo* hanging drop culture approach. **b)** Immunohistochemical staining
53 with BrdU (proliferation marker), cPARP (apoptosis marker) and OCT4 (pluripotency marker) in adult testis
54 tissue containing GCNIS cells treated with SB431542 (20 μ M), recombinant Nodal (50 ng/ml), Activin A (50
55
56
57
58
59
60
61
62
63
64
65

1 ng/ml) or vehicle for 48 h. Sections were counterstained with Mayer's haematoxylin. Scale bar corresponds
2
3 to 100 μm . Quantification of the number of **c)** BrdU⁺ cells per mm^2 , **d)** cPARP⁺ cells per mm^2 and **e)** OCT4⁺
4
5 cells per mm^2 . Number of positive cells is normalised to vehicle controls (set to 1), and only apoptotic
6
7 GCNIS cells were quantified. Tissue from three patients was evaluated (n=3). Top panel of **c-e)** shows
8
9 results from the individual patient samples, while bottom panel represents mean \pm SEM.
10
11
12
13
14

15 **Fig. 4. Effects of manipulating Nodal and Activin signalling in GCNIS cells cultured *ex vivo*.** **a)**
16
17 Immunohistochemical staining with BrdU (proliferation marker), cPARP (apoptosis marker) and OCT4
18
19 (pluripotency marker) in adult testis tissue containing GCNIS cells treated with SB431542 (20 μM),
20
21 recombinant Nodal (50 ng/ml) or vehicle for 4 days. Sections were counterstained with Mayer's
22
23 haematoxylin. Scale bar corresponds to 100 μm . Quantification of the number of **b)** BrdU⁺ cells per mm^2 , **c)**
24
25 cPARP⁺ cells per mm^2 and **d)** OCT4⁺ cells per mm^2 . Number of positive cells is normalised to vehicle controls
26
27 (set to 1), and only apoptotic GCNIS cells were quantified. Tissue from three patients was evaluated (n=3).
28
29 Top panel of **b-d)** shows results from the individual patient samples, while bottom panel represents mean \pm
30
31 SEM.
32
33
34
35
36
37
38
39

40 **Fig 5. Effects of pharmaceutical inhibition of Nodal/Activin or Nodal signalling on cisplatin-sensitivity in**
41
42 **Ntera2 cells.** Ntera2 cells were treated for 48 h with SB431542 (5 μM and 20 μM) or Lefty (100 ng/ml)
43
44 followed by additional 48 h of cisplatin treatment (1 μM and 5 μM) and assessment of cell proliferation. **a)**
45
46 Experiments were conducted in three independent experiments with eight replicates per treatment (shown
47
48 as mean for each experiment). Cell proliferation is set to 1 in Ntera2 cells not treated with cisplatin. **b)**
49
50 Values represent mean \pm SEM from the three independent experiments (n=3). Significant difference
51
52 compared to proliferation of vehicle-treated control Ntera2 cells receiving corresponding cisplatin
53
54 treatment, * P<0.05.
55
56
57
58
59
60
61
62
63
64
65

1 **Fig 6. Effects of siRNA-mediated knockdown of *CRIPTO* expression on cisplatin-sensitivity in NTera2 cells.**

2
3 Expression of *CRIPTO* determined by RT-qPCR after knockdown using a siRNA targeting *CRIPTO* (siCRIPTO)
4
5 and a non-specific siRNA control (siCTRL). *RPS29* was used as reference gene. **a)** Experiments were
6
7 conducted in four independent experiments (n=4) and measured as technical triplicates (shown as mean
8
9 for each experiment). Expression level of *CRIPTO* is set to 1 in vehicle-treated control NTera2 cells. **b)**
10
11 Values represent mean \pm SEM from the four independent experiments. Significant difference compared to
12
13 expression level of *CRIPTO* in siCTRL-transfected NTera2 cells, * P<0.05. Following knockdown, cells were
14
15 subjected to treatment with 1 μ M and 5 μ M cisplatin for 48 h and cell proliferation was assessed. **c)**
16
17 Experiments were conducted in four independent experiments and set up with eight technical replicates
18
19 per treatment. **d)** Values represent mean \pm SEM from the four independent experiments. Cell proliferation
20
21 is set to 1 in vehicle-treated control NTera2 cells not treated with cisplatin.
22
23
24
25
26
27
28

29 **Fig 7. Effects of inhibiting Nodal/Activin signalling on cisplatin-sensitivity in a NTera2 xenograft model.**

30
31 NTera2 cells (2×10^6 ; single injection) were xenografted into the flanks of nude mice and allowed to grow to
32
33 an average size of 150 mm³. Animals were allocated into three groups (n=10 for each group) and treated
34
35 (day 0 on graph) with vehicle (10 mg/kg DMSO i.p. three times weekly), cisplatin (6 mg/kg i.p. once during
36
37 the experiment) or cisplatin + SB431542 (6 mg/kg cisplatin i.p. once during the experiment and 10 mg/kg
38
39 SB431542 i.p. three times weekly). Body weight and tumour size (mm³) were evaluated three times weekly
40
41 during the experimental period of 11 days. Values represent mean \pm SEM. Significant difference compared
42
43 to vehicle control-treated mice, * P<0.05, ** P<0.01 and *** P<0.001. Abbreviations: i.p., intraperitoneal
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


Tables


Table 1. Antibody dilutions, retrieval buffer and details. Antigen-retrieval buffers: citrate buffer, 10 mM, pH 6.0; TEG buffer, 10 mM Tris, 0.5 mM EGTA, pH 9.0.


Antibody	Dilution (formalin)	Retrieval buffer	Species	Company	Cat. Number
OCT4	1:50	TEG	Mouse	Santa Cruz	Sc-5279
NODAL	1:800	Citrate	Mouse	Abcam	Ab55676
CRIPTO	1:200	Citrate	Rabbit	Abcam	Ab19917
LEFTY	1:4000	Citrate	Rabbit	Abcam	Ab22569
cPARP	1:100	Citrate	Rabbit	Cell Signaling	5625
BrdU	1:100	Citrate	Mouse	Dako	M0744


Table 2. Primer sequences.


Gene	Forward primer 5'-3'	Reverse primer 5'-3'	Amplicon size	GenBank Accession no.
<i>OCT4 (POU5F1)</i>	TACTCCTCGGTCCTTTCC	CAAAAACCTGGCACAACT	166 bp	NM_002701
<i>NANOG</i>	TGATTTGTGGCCTGAAGAAA	GAGGCATCTCAGCAGAAGACA	60 bp	NM_024865.4
<i>NODAL</i>	AGCATGGTTTTGGAGGTGAC	CCTGCGAGAGGTTGGAGTAG	160 bp	NM_001329906.1
<i>CRIPTO</i>	TCCTTCTACGGACGGAAGT	ATCACAGCCGGTAGAAATG	153 bp	NM_001174136.1
<i>LEFTY1</i>	GCCTCGACAGTGCATCGCCTC	CAAGTAAACAATGACACATTGGGC	477 bp	NM_020997.4
<i>RPS20</i>	AGACTTTGAGAATCACTACAAGA	ATCTGCAATGGTGACTTCCAC	179 bp	NM_001023
<i>RPS29</i>	CGCTCTTGTCGTCTGTCA	CCTTCGCTACTGACGGAAA	91 bp	NM_001032



















Click here to access/download
Supplementary Material
Suppl Figure 1.docx

